BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 26712690)

  • 1. CD126 and Targeted Therapy with Tocilizumab in Chronic Lymphocytic Leukemia.
    Liu FT; Jia L; Wang P; Farren T; Li H; Hao X; Agrawal SG
    Clin Cancer Res; 2016 May; 22(10):2462-9. PubMed ID: 26712690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 and NF-κB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia.
    Liu FT; Jia L; Wang P; Wang H; Farren TW; Agrawal SG
    Oncotarget; 2016 May; 7(22):32031-45. PubMed ID: 27074565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
    Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
    Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
    Johnston JB; Paul JT; Neufeld NJ; Haney N; Kropp DM; Hu X; Cheang M; Gibson SB
    Leuk Lymphoma; 2004 Oct; 45(10):2017-27. PubMed ID: 15370246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics.
    Choudhary GS; Tat TT; Misra S; Hill BT; Smith MR; Almasan A; Mazumder S
    Oncotarget; 2015 Jul; 6(19):16912-25. PubMed ID: 26219338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine-induced apoptosis of B chronic lymphocytic leukemia cells includes early cleavage of p27kip1 by caspases.
    Sanhes L; Tang R; Delmer A; DeCaprio JA; Ajchenbaum-Cymbalista F
    Leukemia; 2003 Jun; 17(6):1104-11. PubMed ID: 12764376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide.
    Amigo-Jiménez I; Bailón E; Ugarte-Berzal E; Aguilera-Montilla N; García-Marco JA; García-Pardo A
    PLoS One; 2014; 9(6):e99993. PubMed ID: 24956101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin.
    Decker T; Hipp S; Ringshausen I; Bogner C; Oelsner M; Schneller F; Peschel C
    Blood; 2003 Jan; 101(1):278-85. PubMed ID: 12393642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia.
    Wang HQ; Jia L; Li YT; Farren T; Agrawal SG; Liu FT
    J Cell Physiol; 2019 Aug; 234(8):13994-14006. PubMed ID: 30623437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies.
    Al-Harbi S; Choudhary GS; Ebron JS; Hill BT; Vivekanathan N; Ting AH; Radivoyevitch T; Smith MR; Shukla GC; Almasan A
    Mol Cancer; 2015 Nov; 14():185. PubMed ID: 26537004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of B-cell chronic lymphocytic leukemia to Rituximab and Campath-1H and correlation with the expression of cell cycle regulatory proteins.
    Grdisa M
    Croat Med J; 2004 Apr; 45(2):136-41. PubMed ID: 15103748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells.
    Vilpo J; Hulkkonen J; Hurme M; Vilpo L
    Leukemia; 2002 Sep; 16(9):1691-8. PubMed ID: 12200683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine.
    de la Fuente MT; Casanova B; Moyano JV; Garcia-Gila M; Sanz L; Garcia-Marco J; Silva A; Garcia-Pardo A
    J Leukoc Biol; 2002 Mar; 71(3):495-502. PubMed ID: 11867687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
    Ganeshaguru K; Wickremasinghe RG; Jones DT; Gordon M; Hart SM; Virchis AE; Prentice HG; Hoffbrand AV; Man A; Champain K; Csermak K; Mehta AB
    Haematologica; 2002 Feb; 87(2):167-76. PubMed ID: 11836167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of cyclin E in resting and activated B-chronic lymphocytic leukaemia cells: cyclin E/cdk2 as a potential therapeutic target.
    Decker T; Hipp S; Hahntow I; Schneller F; Peschel C
    Br J Haematol; 2004 Apr; 125(2):141-8. PubMed ID: 15059135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiRNA-Mediated Knock-Down of Bcl-2 and Mcl-1 Increases Fludarabine-Sensitivity in CLL-CII Cells.
    Ashofteh N; Amini R; Molaee N; Karami H; Baazm M
    Asian Pac J Cancer Prev; 2021 Jul; 22(7):2191-2198. PubMed ID: 34319043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promising anti-leukemic activity of atorvastatin.
    Żołnierczyk JD; Borowiak A; Hikisz P; Cebula-Obrzut B; Błoński JZ; Smolewski P; Robak T; Kiliańska ZM
    Oncol Rep; 2013 May; 29(5):2065-71. PubMed ID: 23440293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.
    Willmore E; Elliott SL; Mainou-Fowler T; Summerfield GP; Jackson GH; O'Neill F; Lowe C; Carter A; Harris R; Pettitt AR; Cano-Soumillac C; Griffin RJ; Cowell IG; Austin CA; Durkacz BW
    Clin Cancer Res; 2008 Jun; 14(12):3984-92. PubMed ID: 18559621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.